An investigator-sponsored Phase 1/2 clinical trial (CRSPA) at St. Jude Children’s Research Hospital (SJCRH) is investigating Auxora^TM as a potential therapy in pediatric patients that develop AAP as a result of treatment for their underlying ALL.

This study is expected to provide valuable information on the use of Auxora^TM in critically ill pediatric patients. Patients enrolled in this trial are treated with four daily doses of Auxora^TM with the primary endpoints of safety, tolerability, and the reduction in development of complications of AAP. A meeting with the FDA is expected to start in H1 2023 to discuss the results of this trial to inform the development path forward.

For more details on the clinical trial, please visit: Study of Auxora to Reduce the Severity of Pancreatitis Due to Asparaginase

Information on our Expanded Access Policy can be obtained through the following link.